Psilera Raises $8.8M in Seed Funding to Accelerate Neuroplastogen

The company plans to use the funds to move its lead clinical program, PSIL-006, toward its first human trials in 2027.

PSIL-006 is a new type of neuroplastogen designed to provide the therapeutic benefits of psychedelic compounds while reducing hallucinogenic side effects and cardiovascular risks.

"This funding marks a pivotal inflection point for Psilera," said Dr. Chris Witowski, Co-Founder and CEO of Psilera. "With the continued support of our investors, we are now fully resourced to transition from a discovery-stage research company to a clinical stage organization. Our mission is to provide safe, effective and accessible treatments for patients suffering from a range of neurological conditions and this capital ensures we remain on track for our first in human trials in 2027."

Read More:Kubera Health Raises $6.5M in Seed Funding Led by Upfront Ventures

Dr. Witowski continued, "We are pleased to see support by the Administration to increase access to psychedelic drugs and expedite the development of innovative treatments with the recently signed U.S. Executive Order, 'Accelerating Medical Treatments for Serious Mental Illness.' With the renewed focus from key regulatory agencies, we look forward to working with them to develop PSIL-006 fully."

About Psilera

Founded in 2019 by Jackie von Salm and Chris Witowski, Psilera develops next-generation psychedelic-inspired therapies and neuroplastogens. The company is building a pipeline of new therapeutic compounds, including its lead program, PSIL-006. Psilera focuses on creating precise neuropharmacology-based treatments designed to improve patient outcomes and experiences.

Read More:Volt Harbor Raises $2M in Seed Funding Led by MFV Partners